FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pierre Fargeot

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Aude Fléchon; Gwenaelle Gravis; F Joly; Stéphane Oudard; D Perol; Damien Pouessel; Frank Priou; Sylvie Zanetta; G Deplanque; Jean Pierre Droz; Pierre Fargeot; C Ferlay; Philippe Beuzeboc; Stéphane Culine
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Jérôme Fayette; Nicolas Penel; Christine Chevreau; Jean-Yves Blay; Didier Cupissol; Antoine Thyss; Cécile Guillemet; Maria Rios; Frédéric Rolland; Pierre Fargeot; Jacques Olivier Bay; Simone Mathoulin-Pelissier; Jean-Michel Coindre; Binh Bui-Nguyen
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Sylvie Négrier; David Perol; Alain Ravaud; Jacques O Bay; Stéphane Oudard; Sylvie Chabaud; Pierre Fargeot; Remy Delva; Gael Deplanque; Gwenaelle Gravis; Bernard Escudier
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pierre Fargeot (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Aude Fléchon; Gwenaelle Gravis; F Joly; Stéphane Oudard; D Perol; Damien Pouessel; Frank Priou; Sylvie Zanetta; G Deplanque; Jean Pierre Droz; Pierre Fargeot; C Ferlay; Philippe Beuzeboc; Stéphane Culine
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(11):2476-81.
2009: Jérôme Fayette; Nicolas Penel; Christine Chevreau; Jean-Yves Blay; Didier Cupissol; Antoine Thyss; Cécile Guillemet; Maria Rios; Frédéric Rolland; Pierre Fargeot; Jacques Olivier Bay; Simone Mathoulin-Pelissier; Jean-Michel Coindre; Binh Bui-Nguyen
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Investigational new drugs 2009;27(5):482-9.
2008: Sylvie Négrier; David Perol; Alain Ravaud; Jacques O Bay; Stéphane Oudard; Sylvie Chabaud; Pierre Fargeot; Remy Delva; Gael Deplanque; Gwenaelle Gravis; Bernard Escudier
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5907-12.
2008: Stéphane Culine; Andrew Kramar; Christine Théodore; Lionel Geoffrois; Christine Chevreau; Pierre Biron; Binh Bui Nguyen; JF Héron; Pierre Kerbrat; Armelle Caty; Rémi Delva; Pierre Fargeot; Karim Fizazi; Jeannine Bouzy; Jean Pierre Droz
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):421-7.
2007: Pierre Kerbrat; Henri Roché; Jacques Bonneterre; Corinne Veyret; Alain Lortholary; Alain Monnier; Pierre Fumoleau; Pierre Fargeot; Moïse Namer; Philippe Chollet; Marie-Josèphe Goudier; Bruno Audhuy; H Simon; Philippe Montcuquet; Jean-Christophe Eymard; S Walter; Pierre Clavère; Jean-Paul Guastalla
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
British journal of cancer 2007;96(11):1633-8.
2006: Corinne Veyret; Christelle Levy; Philippe Chollet; Yacine Merrouche; Henri Roche; Pierre Kerbrat; Pierre Fumoleau; Pierre Fargeot; Pierre Clavere; Bernard Chevallier
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Cancer 2006;107(11):2535-44.
2006: Cécile Molucon-Chabrot; Nicolas Isambert; Laurent Benoit; Sylvie Zanetta; Jean Fraisse; Jean-Claude Guilland; Bernard Royer; Pascale Monin-Baroille; Michel Flesch; Pierre Fargeot; Bruno Coudert; Françoise Mayer; Pierre Fumoleau; Bruno Chauffert
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Anti-cancer drugs 2006;17(10):1211-7.
2006: Michel Héry; Jacques Bonneterre; Henri Roché; Elisabeth Luporsi; Pierre Kerbrat; Moïse Namer; Pierre Fumoleau; Alain Monnier; Pierre Fargeot
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.
Bulletin du cancer 2006;93(10):E109-14.
2006: Henri Roché; Pierre Kerbrat; Jacques Bonneterre; Pierre Fargeot; Pierre Fumoleau; Alain Monnier; Pierre Clavère; Marie-Josèphe Goudier; Philippe Chollet; Jean-Paul Guastalla; Daniel Serin
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1221-7.
2006: Moïse Namer; Pierre Fargeot; Henri Roché; Mario Campone; Pierre Kerbrat; Pascale Romestaing; Alain Monnier; Elisabeth Luporsi; Philippe Montcuquet; Jacques Bonneterre
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):65-73.
2006: Walter Fiedler; N Tchen; J Bloch; Pierre Fargeot; Roberto Sorio; J B Vermorken; L Collette; D Lacombe; Chris Twelves
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
European journal of cancer (Oxford, England : 1990) 2006;42(2):200-4.
2006: Pierre Fumoleau; Henri Roché; Pierre Kerbrat; Jacques Bonneterre; Pascale Romestaing; Pierre Fargeot; Moïse Namer; Alain Monnier; Philippe Montcuquet; Marie-Josèphe Goudier; Elisabeth Luporsi
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):85-92.
2005: Mario Campone; Henri Roché; Pierre Kerbrat; Jacques Bonneterre; Pascale Romestaing; Pierre Fargeot; Moïse Namer; Alain Monnier; Philippe Montcuquet; Marie-Josèphe Goudier; Pierre Fumoleau
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1343-51.
2005: Claudio Praga; Jonas Bergh; Judith Bliss; Jacques Bonneterre; Bruno Cesana; R Charles Coombes; Pierre Fargeot; Annika Folin; Pierre Fumoleau; Rosa Giuliani; Pierre Kerbrat; Michel Hery; Jonas Nilsson; Francesco Onida; Martine Piccart; Lois Shepherd; Patrick Therasse; Jacques Wils; David Rogers
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4179-91.
2005: Jacques Bonneterre; Henri Roché; Pierre Kerbrat; Alain Brémond; Pierre Fumoleau; Moïse Namer; Marie-Josèphe Goudier; Simon Schraub; Pierre Fargeot; Isabelle Chapelle-Marcillac
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2686-93.
2004: Pierre Fargeot; Jacques Bonneterre; Henri Roché; Alain Lortholary; Mario Campone; Isabelle Van Praagh; Alain Monnier; Moïse Namer; Simon Schraub; Jean-Claude Barats; Jean-Paul Guastalla; Marie-Josèphe Goudier; Isabelle Chapelle-Marcillac
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4622-30.
2004: Juliette Thariat; Michel Toubeau; Paul Ornetti; Bruno Coudert; Alina Berrielo-Riedinger; Pierre Fargeot; Christian Tavernier; François Brunotte; Jean-Francis Maillefert
Sensitivity and specificity of thallium-201 scintigraphy for the diagnosis of malignant vertebral fractures.
European journal of radiology 2004;51(3):274-8.
2004: Jacques Bonneterre; Henri Roché; Pierre Kerbrat; Pierre Fumoleau; Marie-Josèphe Goudier; Pierre Fargeot; Philippe Montcuquet; Pierre Clavère; Jean-Claude Barats; Alain Monnier; Corinne Veyret; Jean Datchary; Isabelle Van Praagh; Isabelle Chapelle-Marcillac
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3070-9.
2004: andrew bottomley; Laura Biganzoli; Tanja Cufer; Robert E Coleman; Corneel Coens; Fabio Efficace; Hilary Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; Martine Piccart
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2576-86.
2004: Fabio Efficace; Laura Biganzoli; Martine Piccart; Corneel Coens; Kristel van Steen; Tanja Cufer; R E Coleman; Hilary Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; andrew bottomley
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(7):1021-30.
2004: R Deporte-Fety; N Simon; Pierre Fumoleau; Mario Campone; Pierre Kerbrat; Jacques Bonneterre; Pierre Fargeot; S Urien
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2004;53(3):233-8.
2003: S Urien; Pierre Fumoleau; Mario Campone; Pierre Kerbrat; Jacques Bonneterre; Pierre Fargeot; R Deporte-Fety
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 2003;52(2):99-107.
2003: Pierre Fumoleau; Pierre Kerbrat; Pascale Romestaing; Pierre Fargeot; Alain Brémond; Moïse Namer; Simon Schraub; Marie-Josèphe Goudier; Jeanne Mihura; Alain Monnier; Pierre Clavère; Daniel Serin; Philippe Seffert; Christiane Pourny; Thomas Facchini; Jean-Philippe Jacquin; Jean-François Sztermer; Jean Datchary; René Ramos; Elisabeth Luporsi
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):298-305.
2002: Jacques Bonneterre; Henri Roché; Alain Monnier; Jean-Paul Guastalla; Moïse Namer; Pierre Fargeot; Sylvie Assadourian
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
British journal of cancer 2002;87(11):1210-5.
2002: Laura Biganzoli; Tanja Cufer; Peter Bruning; R Coleman; Luc Duchateau; A H Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; R Epelbaum; Caroline Lohrisch; Martine J Piccart
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3114-21.
2002: Jean-Marc Riedinger; N Eche; Jean-Pierre Basuyau; Alain Daver; Claude Touzery; Françoise Mayer; Bruno Coudert; Pierre Fargeot; Bruno Chauffert; C de Gislain; Sylvie Zanetta
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles].
Annales de biologie clinique 2002;60(2):183-91.
2001: Nicolas Isambert; Maria Correia; Jean-Pierre Cercueil; Sylvie Zanetta; Liliana Osmak; Michel Flesch; Denis Krause; Bruno Coudert; Pierre Fargeot; Laurent Bedenne; Bruno Chauffert
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.
Journal of experimental & clinical cancer research : CR 2001;20(2):183-8.
2000: Agnès Laplanche; L Alzieu; Thierry Delozier; J Berlie; Corinne Veyret; Pierre Fargeot; Monique Luboinski; J Lacour
Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC).
Breast cancer research and treatment 2000;64(2):189-91.
2000: Pierre Fumoleau; R Déporte; Pierre Kerbrat; Jacques Bonneterre; Pierre Fargeot
UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):50-5.
2000: G Bastian; Jean-François Seitz; V Moutardier; J R Delperro; Pierre Fargeot; Jean Fraisse; Patricia Formento; M Chazard; Nicole Renée; Gérard Milano
Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):35-7.
2000: H Roche; Hervé Cure; Antoine Adenis; Pierre Fargeot; C Terret; MA Lentz; Jean-Claude Madelmont; Pierre Fumoleau; A Hanausk; Philippe Chollet
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.
Journal of neuro-oncology 2000;49(2):141-5.
2000: M Arnal; Noreli Franco; Pierre Fargeot; Jean-Marc Riedinger; P Brunet-Lecomte; Sarab Lizard-Nacol
Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer.
Breast cancer research and treatment 2000;61(1):13-20.
1999: Hervé Cure; Pierre Souteyrand; R Ouabdesselam; H Roche; A Ravaud; Michel D'Incan; Patrice Viens; Pierre Fargeot; MA Lentz; Pierre Fumoleau; Axel R Hanauske; Philippe Chollet
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Melanoma research 1999;9(6):607-10.
1999: Catherine Lhommé; Pierre Fumoleau; Pierre Fargeot; Y Krakowski; V Dieras; Jean Chauvergne; P Vennin; P Rebattu; H Roche; Jean-Louis Misset; M A Lentz; Martine Van Glabbeke; A Matthieu-Boué; Dominique Mignard; Bernard Chevallier
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3136-42.
1999: Sarab Lizard-Nacol; P Genne; Bruno Coudert; Jean-Marc Riedinger; M Arnal; C Sancy; P Brunet-Lecomte; Pierre Fargeot
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Anticancer research 1999;19(4C):3575-81.
1999: Sarab Lizard-Nacol; Bruno Coudert; P Colosetti; Jean-Marc Riedinger; Pierre Fargeot; P Brunet-Lecomte
Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.
Breast cancer research : BCR 1999;1(1):81-7.
1998: Marian Degardin; J Oliveira; L Geoffrois; Frédéric Rolland; Jean-Pierre Armand; P Bastit; Jean Chauvergne; Pierre Fargeot; Martine Van Glabbeke; M A Lentz; P Tresca; J Boudillet; Pierre Fumoleau; P Cappelaere
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1103-7.
1997: Jean-Marc Riedinger; Bruno Coudert; Isabelle Barillot; G Buffenoir; Françoise Mayer; Pierre Fargeot; Jean Cuisenier; J Guerrin
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
Bulletin du cancer 1997;84(9):855-60.
1996: Bruno Coudert; C De Gislain; J L Beltramo; B Guigues; F Mayer; Y Bruchon; Jean-Marc Riedinger; Pierre Fargeot; M Dumas; J Guerrin
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
Bulletin du cancer 1996;83(10):847-52.
1996: Jean-Marc Riedinger; Isabelle Barillot; Bruno Coudert; Pierre Fargeot; A Berriolo-Riedinger; J Guerrin
[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Bulletin du cancer 1996;83(8):654-63.
1996: M Degardin; P Cappelaere; I Krakowski; Pierre Fargeot; Didier Cupissol; S Brienza
Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
European journal of cancer. Part B, Oral oncology 1996;32B(4):278-9.
1996: J L Misset; M di Palma; M Delgado; R Plagne; P Chollet; Pierre Fumoleau; B Le Mevel; D Belpomme; J Guerrin; Pierre Fargeot; R Metz; M Ithzaki; C Hill; G Mathé
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1136-45.
1996: V Urosevic; Philippe Chollet; Antoine Adenis; Jean Chauvergne; Pierre Fargeot; H Roche; P Kerbrat; MA Lentz; Pierre Fumoleau; Bernard Chevallier
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):181-2.
1995: Binh Nguyen Bui; B Chevallier; Christine Chevreau; I Krakowski; A M Peny; A Thyss; C Maugard-Louboutin; Didier Cupissol; Pierre Fargeot; Françoise Bonichon
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2629-36.
1995: Bernard Chevallier; Philippe Chollet; Y Merrouche; H Roche; Pierre Fumoleau; P Kerbrat; J Y Genot; Pierre Fargeot; J P Olivier; C Fizames
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1564-71.
1995: Jean Chauvergne; P Kerbrat; Antoine Adenis; Philippe Chollet; Pierre Fargeot; Eric Pujade-Lauraine; Véronique Dieras; J C Madelmont; MA Lentz; C Toulouse
Phase II study of cystemustine in advanced renal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):130-1.
1994: E Garcia-Giralt; C Omodei Zorini; L Ferri; Y Ayme; M Carton; A Daban; Thierry Delozier; Pierre Fargeot; Pierre Fumoleau; A Gorins
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
La Clinica terapeutica 1994;145(8):113-21.
1993: Jean Chauvergne; Catherine Lhommé; J Rohart; J F Héron; Y Ayme; A Goupil; Pierre Fargeot; M David
[Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients].
Bulletin du cancer 1993;80(12):1069-79.
1993: Henri Roché; N Guiochet; P Kerbrat; P Rebattu; Pierre Fargeot; A Cattan; Jean-Pierre Armand; R Keiling; M A Lentz; M Van Glabeke
Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
American journal of clinical oncology 1993;16(2):137-9.
1993: J Douchez; Jean Pierre Droz; B Desclaux; Y Allain; Pierre Fargeot; Armelle Caty; P Charrot
Quality of life in long-term survivors of nonseminomatous germ cell testicular tumors.
The Journal of urology 1993;149(3):498-501.
1993: Bernard Chevallier; S Leyvraz; J P Olivier; Pierre Fargeot; T Facchini; M L Vo Van
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
Cancer investigation 1993;11(2):135-9.
1993: Christine Chevreau; J P Droz; J L Pico; P Biron; P Kerbrat; Hervé Cure; J F Héron; B Chevallier; Pierre Fargeot; A Kramar
Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial.
European urology 1993;23(1):213-7; discussion 218.
1993: Pierre Fumoleau; Y Devaux; M L Vo Van; P Kerbrat; Pierre Fargeot; S Schraub; J Mihura; M Namer; M Mercier
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Drugs 1993;45 Suppl 2():38-45.
1992: E Garcia-Giralt; Y Ayme; M Carton; A Daban; Thierry Delozier; Pierre Fargeot; Pierre Fumoleau; A Gorins; D Guerin; R Guerin
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Breast cancer research and treatment 1992;24(2):139-45.
1992: Marie-Françoise Avril; J Bonneterre; Didier Cupissol; Jean-Jacques Grob; B Kalis; Pierre Fumoleau; P Kerbrat; L Israel; Pierre Fargeot; D Lambert
Fotemustine plus dacarbazine for malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1992;28A(11):1807-11.
1991: Jacques Bonneterre; P Kerbrat; Pierre Fargeot; R Metz; H Roche; P Bastit; A Chevrier; M Tubiana-Hulin; G Geyer; P Cappelaere
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(7):849-52.
1991: A Boutan-Laroze; Mondher Mahjoubi; Jean Pierre Droz; P Charrot; Pierre Fargeot; P Kerbrat; Armelle Caty; P M Voisin; Marc Spielmann; Annie Rey
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1690-4.
1990: C de Gislain; M Dumas; P d'Athis; T Chapuis; F Mayer; Pierre Fargeot; J Guerrin; A Escousse
[Course of blood creatinine during repeated injections of cisplatin. Influence of drug combinations].
Thérapie 1990;45(5):423-7.
1990: Jacques Bonneterre; B Chevallier; R Metz; Pierre Fargeot; Eric Pujade-Lauraine; M Spielmann; M Tubiana-Hulin; D Paes; J Bons
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):1063-9.
1990: Jean Chauvergne; J Rohart; J F Héron; Y Aymé; J Berlié; Pierre Fargeot; M George; D Lebrun-Jezekova; J Pigneux; C Chenal
[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].
Bulletin du cancer 1990;77(10):1007-24.
1990: P Cappelaere; J Vignoud; Pierre Fargeot; R Metz; Jean Chauvergne; L Meeus; M Schneider; M Chazard
[Palliative chemotherapy of epidermoid carcinoma of the upper respiratory and digestive tracts with a combination of carboplatin and 5-fluorouracil].
Bulletin du cancer 1990;77(11):1099-105.
1990: Pierre Fargeot
[Germ cell testicular tumors. Three therapeutic periods].
Bulletin du cancer 1990;77(4):331-9.
1989: Tony Petrella; J F Michiels; R Michiels; Françoise Collin; J M Nabholtz; S Friedman; Pierre Fargeot
CD 15 antigen in Hodgkin's disease.
Pathology, research and practice 1989;185(6):886-90.
1989: H Lupera; Jean Pierre Droz; G Piot; P Lapleige; Pierre Fargeot; Christine Theodore
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Oncology 1989;46(6):372-4.
1988: Jacques Bonneterre; L Mauriac; B Weber; H Roche; Pierre Fargeot; M Tubiana-Hulin; M Sevin; P Chollet; P Cappelaere
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
European journal of cancer & clinical oncology 1988;24(12):1851-3.
1988: Pierre Pfitzenmeyer; F Massin; Pierre Fargeot; P Bonneau; R Michiels; L Jeannin
[Pulmonary amyloidosis of the AA type associated with Hodgkin's disease].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1988;9(5):524-7.
1988: Jean Chauvergne; P Cappelaere; B Clavel; M David; Pierre Fargeot; L Meeus; L Traissac; T Klein
[Randomized trial of initial chemotherapy with cisplatin alone or in combination in 241 advanced carcinomas of the upper respiratory and digestive tract].
Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris 1988;105(8):581-9.
1988: Jean Chauvergne; P Cappelaere; Pierre Fargeot; L Meeus; J Gary-Bobo; T Klein; B Clavel; M David
[A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck. Analysis of a series of 209 patients].
Bulletin du cancer 1988;75(1):9-22.
1987: Jean Pierre Droz; Pierre Fargeot; P Laplaige; A Moran-Ribon; G Piot
Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
Progress in clinical and biological research 1987;243B():235-42.
1986: P Hurteloup; Jean-Pierre Armand; P Cappelaere; R Metz; P Kerbrat; R Keiling; Pierre Fumoleau; Pierre Fargeot; S Schraub; P Bastit
Phase II clinical evaluation of doxifluridine.
Cancer treatment reports 1986;70(6):731-7.
1986: Jacques Bonneterre; H Coppens; L Mauriac; J Rouesse; Pierre Fargeot; R Metz; J P Armand; A Mathieu; M Tubiana; P Cappelaere
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Acta clinica Belgica. Supplementum 1986;11():41-8.
1985: Jacques Bonneterre; H Coppens; L Mauriac; M Metz; J Rouesse; J P Armand; Pierre Fargeot; M Mathieu; M Tubiana; P Cappelaere
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
European journal of cancer & clinical oncology 1985;21(10):1153-8.
1984: R De Jager; P Cappelaere; Jean-Pierre Armand; R Keiling; Pierre Fargeot; P Bastit; M van Glabbeke; J Renard; H Earl; R Rubens
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
European journal of cancer & clinical oncology 1984;20(11):1369-75.
1984: Pierre Fargeot; J Guerrin
[Role of chemotherapy in adjuvant treatment of breast cancer: modulation of the immune status].
Bulletin du cancer 1984;71(4):346-53.
1980: J Guerrin; Pierre Fargeot; C de Gislain; F Mayer; H Rodriguez; F Massin
[Adjuvant chemotherapy in treatment of non seminomatous germinal testicular tumor. Results and reflexions about 77 cases (author's transl)].
La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris 1980;56(5-6):209-13.